Defined by the absence of expression of the ER, PR, and HER-2, TNBC accounts for 15% to 20% of all breast cancers (4), which exhibits high heterogeneity and complex biological characteristics, posing challenges in establishing a unified biological model. Here, ERBB2 is linked to breast cancer.